ACSL1

Long-chain-fatty-acid--CoA ligase 1 · P33121 · ACSL1 on Sugi Atlas →

3,270 patent compounds predicted against ACSL1, 1,545 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5417997	0.49	11/20
SCHEMBL664031	0.51	10/20
SCHEMBL10147937	0.51	10/20
SCHEMBL2469558	0.54	9/20
SCHEMBL2469560	0.54	9/20
SCHEMBL10185204	0.49	7/20
SCHEMBL1749499	0.56	5/20
SCHEMBL1247012	0.73	4/20
SCHEMBL9413588	0.62	4/20
SCHEMBL9648991	0.57	4/20
SCHEMBL8642144	0.55	4/20
Trifluoroacetic Acid (SCHEMBL1794473)	0.55	4/20
Trifluoroacetic Acid (SCHEMBL1796405)	0.55	4/20
SCHEMBL7046750	0.51	4/20
SCHEMBL8016519	0.47	4/20
Hydrochloric Acid (SCHEMBL8900021)	0.46	4/20
Acetic Acid (SCHEMBL3368203)	0.46	4/20
Acetic Acid (SCHEMBL3523609)	0.45	4/20
SCHEMBL8203511	0.45	4/20
Hydrochloric Acid (SCHEMBL8712886)	0.45	4/20

Clinical trials — most relevant to ACSL1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Comparison of Coenzyme A and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia	PHASE3	COMPLETED
Bezafibrate Trial in CPT2 Deficiency	PHASE3	UNKNOWN
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease	PHASE2	COMPLETED
Acetylcarnitine and Insulin Sensitivity	PHASE2	COMPLETED
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC	PHASE1/PHASE2	UNKNOWN
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis	PHASE2	UNKNOWN
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients	PHASE2	COMPLETED
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects	PHASE2	COMPLETED
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease	EARLY_PHASE1	COMPLETED
Fatty Acid Oxidation Defects and Insulin Sensitivity	nan	COMPLETED
Lifestyle Intervention in Preparation for Pregnancy (LIPP)	nan	COMPLETED
Androgens and NAFLD Longitudinal Cohort Study	nan	RECRUITING
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study	nan	COMPLETED
The Roles of SAH Gene Family in Athrogenic Dyslipidemia in Postmenopausal Women	nan	UNKNOWN
Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise	nan	COMPLETED
Familial Partial Lipodystrophy Study	nan	COMPLETED
Exercise Intolerance Study in Long Chain Fatty Acid Oxidation Disorders	nan	RECRUITING
Impact Of Choline in Patients With NAFLD	nan	UNKNOWN
Effect of Dietary SFA and Fructose on Hepatic Insulin Sensitivity	nan	COMPLETED
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome	nan	UNKNOWN
De Novo Lipogenesis in Severity of NAFLD	nan	COMPLETED
Systemic Biomarkers of Brain Injury From Hyperammonemia	nan	RECRUITING
Screening of Healthy Adults for Genetic Variations That Control Fatty Acid Processing	nan	COMPLETED
Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD)	nan	COMPLETED
Metabolic Effects of Medium-Chain Fatty Acids in Patients With Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Healthy Individuals	nan	RECRUITING
Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN)	nan	UNKNOWN
Hepatic Glycogen and Fat Oxidation	nan	COMPLETED
Hepatic Energy Fluxes in NASH and NAS Patients	nan	ACTIVE_NOT_RECRUITING
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
11C-Acetate PET/CT Non-FDG-Avid Tumors	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ACSL1 binder may also engage these)

Protein	Name	Similarity
P18163	—	1.000	P18163 →
P41216	—	0.998	P41216 →
Q9JID6	—	0.997	Q9JID6 →
Q91WC3	—	0.991	Q91WC3 →
P33124	—	0.986	P33124 →
ACSL6	Long-chain-fatty-acid--CoA ligase 6	0.974	landscape →
O88813	—	0.973	O88813 →
Q8JZR0	—	0.966	Q8JZR0 →
ACSL5	Long-chain-fatty-acid--CoA ligase 5	0.966	landscape →
Q4R3Y4	—	0.964	Q4R3Y4 →
Q6P1M0	—	0.960	Q6P1M0 →
Q5RDY4	—	0.960	Q5RDY4 →
Q28BL6	—	0.957	Q28BL6 →
Q9VE51	—	0.956	Q9VE51 →
Q5RFI8	—	0.954	Q5RFI8 →
Q8LPS1	—	0.953	Q8LPS1 →
P97849	—	0.952	P97849 →
Q60676	—	0.952	Q60676 →
Q91VE0	—	0.951	Q91VE0 →
P53042	—	0.951	P53042 →
Q9D0L4	—	0.950	Q9D0L4 →
Q99P39	—	0.950	Q99P39 →
Q9ER35	—	0.950	Q9ER35 →
Q60714	—	0.950	Q60714 →
Q8GWU0	—	0.950	Q8GWU0 →
Q9Z1J3	—	0.949	Q9Z1J3 →
Q7TSV4	—	0.948	Q7TSV4 →
PPP5C	Serine/threonine-protein phosphatase 5	0.948	landscape →
LDHA	L-lactate dehydrogenase A chain	0.948	landscape →
GLS2	Glutaminase liver isoform, mitochondrial	0.948	landscape →